Genotoxic assessment and toxicity evaluation of peginesatide in CByB6F1 hybrid mice

References

• Duliege, A. M., Lambert, J., Pickup, M., Iwashita, J., Schatz, P., Chen, M. J., et al. (2005). Pharmacokinetic (PK) profile of single IV doses of Hematide™, a novel, synthetic, pegylated peptide that stimulates erythropoiesis. J Am Soc Nephrol 16: PUB615, 916A.
   Google Scholar
• Evans, H. J. (1976). Cytological methods for detecting chemical mutagens. In: Hollaender, A. (Ed.), Chemical mutagens, principles and methods for their detection, vol 4. New York: Plenum.
   Google Scholar
• Fan, Q., Leuther, K. L., Holmes, C. P., Fong, K. L., Zhang, J., Velkovska, S., et al. (2006). Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent for the treatment of anemia. Exp Hematol 34:1303–1311.
   PubMed Web of Science ®Google Scholar
• Fisher, J. W. (2003). Erythropoietin: physiology and pharmacology update. Soc Exp Biol Med 228:1–14.
   PubMed Web of Science ®Google Scholar
• Hayashi, M., Tice, R. R., MacGregor, J. T., Anderson, D., Blakey, D. H., Kirsch-Volders, M., et al. (1994). In vivo rodent erythrocyte micronucleus assay. Mutat Res 312:293–1304.
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. (1998). S1B: Testing for Carcinogenicity of Pharmaceuticals. Federal Register 63:8983.
   PubMedGoogle Scholar
• International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. (1996). S2A: Specific Aspects of Regulatory Genotoxicity Tests for Pharmaceuticals. Federal Register 61:18198–18202.
   Google Scholar
• International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. (1997). S2B: Genotoxicity: A Standard Battery for Genotoxicity Testing of Pharmaceuticals. Federal Register 62:16026–16030.
   Google Scholar
• International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. (1997). S6: Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. Federal Register 62:61515–61519.
   Google Scholar
• Kastenbaum, M. A., Bowman, K. O. (1970). Tables for determining the statistical significance of mutation frequencies. Mutat Res 9:527–549.
   PubMed Web of Science ®Google Scholar
• Latimer, K. S., Mahaffey E. A., Prasse, K. W. (Eds.). (2003). Duncan & Prasse’s veterinary laboratory medicine: clinical pathology, 4th ed. Ames, Iowa, USA: Wiley-Blackwell.
   Google Scholar
• Macdougall, I., Geronemus, R., Ardelean, L., Pergola, P., DeSilva, V., Zeig, S., et al. (2008). Interim evaluation of long-term safety and tolerability of Hematide during maintenance treatment of anemia in patients with chronic kidney disease on hemodialysis and not on hemodialysis. J Am Soc Nephrol 19:278A.
   Google Scholar
• Macdougall, I. C. (2008). Novel erythropoiesis-stimulating agents: a new era in anemia management. Clin J Am Soc Nephrol 3:200–207.
   PubMed Web of Science ®Google Scholar
• Maron, D. M., Ames B. N. (1983). Revised methods for the Salmonella mutagenicity test. Mutat Res 113:173–215.
   PubMed Web of Science ®Google Scholar
• Morton, D., Alden, C. L., Roth, A. J., Usui, T. (2002). The Tg.rasH2 mouse in cancer hazard identification. Toxicol Pathol 30:139–146.
   PubMed Web of Science ®Google Scholar
• OECD Guideline for the Testing of Chemicals. (1998). OECD Guideline 474 (Genetic Toxicology: Mammalian Erythrocytes Micronucleus Test), Ninth Addendum to the OECD Guidelines for the Testing of Chemicals. Paris: OECD.
   Google Scholar
• Ouyang, Y. (2007). FDA Toxicologist’s Review of Pegserepoetin Beta (Mircera) BLA 125164. Washington, DC: Food and Drug Administration, Department of Health and Human Services, Center for Drug Evaluation and Research Report No. STN125164.
   Google Scholar
• Pritchard, J. B., French, J. E., Davis, B. J., Haseman, J. K. (2003). The role of transgenic mouse models in carcinogen identification. Environ Health Perspect 111:444–454.
   PubMed Web of Science ®Google Scholar
• Schiller, B., Doss, S., De Cook, E., Del Aguila, M. A., Nissenson, A. R. (2008). Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study. Hemodial Int 12:441–449.
   PubMed Web of Science ®Google Scholar
• Serabian, M. A. (2001). FDA Toxicologist’s Review of Darbepoetin Alfa, BLA 99–1492. Washington, DC: Food and Drug Administration, Department of Health and Human Services, Center for Drug Evaluation and Research Report No. STN103951.
   Google Scholar
• Stead, R. B., Lambert, J., Wessels, D., Iwashita, J. S., Leuther, K. K., Woodburn, K. W., et al. (2006). Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteer. Blood 108:1830–1834.
   PubMed Web of Science ®Google Scholar
• Swierenga, S. H. H., Heddle, J. A., Sigal, E. A., Gilman, J. P. W., Brillinger, R. L., Douglas, G. R., et al. (1991). Recommended protocols based on a survey of current practice in genotoxicity testing laboratories, IV. Chromosome aberration and sister-chromatid exchange in Chinese hamster ovary, V79 Chinese lung, and human lymphocyte cultures. Mutat Res 246:301–322.
   PubMed Web of Science ®Google Scholar
• Tamaoki, N. (2001). The rasH2 transgenic mouse: nature of the model and mechanistic studies on tumorigenesis. Toxicol Pathol 29:81–89.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. (1996). Guide for the Care and Use of Laboratory Animals. Prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources. Commission of Life Sciences, National Research Council. Washington, DC: National Academy Press.
   Google Scholar
• Weiss, G., Goodnough, L. T. (2005). Anemia of chronic disease. NEJM 352:1011–1023.
   PubMed Web of Science ®Google Scholar
• Woodburn, K. W., Wilson, S. D., Fong, K. L, Schatz, P. J., Ferrell, T., Spainhour, C. B., et al. (2008). Chronic preclinical safety evaluation of Hematide, a pegylated peptidic erythropoiesis stimulating agent in monkeys. Haematologica 93:1376–1379.
   PubMed Web of Science ®Google Scholar
• Woodburn, K. W., Wilson, S. D., Fong, K-L., Schatz, P. J, Spainhour, C. B., Norton, D. (2009). Chronic pharmacological and safety evaluation of Hematide, a PEGylated peptidic erythropoiesis stimulating agent, in rodents. Basic Clin Pharmacol Toxicol 104:155–163.
   PubMed Web of Science ®Google Scholar
• Woodburn, K. W., Fan, Q., Schatz, P. J., Wilson, S. D., Fong, K. L, Norton, D. (2010). A subchronic murine intravenous pharmacokinetic and toxicity study of Hematide, a PEGylated peptidic erythropoiesis-stimulating agent. Drug Chem Toxicol 33: 28–37.
   PubMed Web of Science ®Google Scholar